06Dec 2024
Infliximab No Better than Placebo for Back Pain

Infliximab No Better than Placebo for Back Pain

The multicenter, randomized, triple-blind trial assessed the efficacy of infliximab in patients with chronic low back pain and Modic changes type 1. Conducted in Norway, 128 participants received either infliximab or placebo over 5 months. The primary outcome, the Oswestry Disability Index (ODI) score, showed an average change of -7.0 in the infliximab group and -6.4 in the placebo group, with no significant difference (1.3 points; p=0.45). Secondary outcomes also showed no benefit. Adverse event rates were similar between groups. Infliximab did not outperform placebo in reducing pain or disability.

  • #rheumatology

Like

Save

Share